Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions

References

• Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics 2004. CA Cancer J Clin 2004; 54: 8–29
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward W, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005; 55: 10–30
   PubMed Web of Science ®Google Scholar
• The National Board of Health and Welfare. Cancer incidence in Sweden. Health Dis 2004:66.
   Google Scholar
• Hjelmgren J, Ceberg J, Persson U, Alvegård TA. The cost of treating pancreatic cancer: a cohort study based on patients’ records from four hospitals in Sweden. Acta Oncol 2003; 42: 218–26
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200–10
   PubMed Web of Science ®Google Scholar
• Andersson R, Vagianos CE, Williamson CRN. Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. HPB 2004; 6: 5–12
   PubMedGoogle Scholar
• Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first–line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403–13
   PubMed Web of Science ®Google Scholar
• Ishii H, Furuse J, Nagase M, Yoshino M. Impact of gemcitabine on the treatment of metastatic pancreatic cancer. J Gastroenterol Hepatol 2005; 20: 62–6
   PubMed Web of Science ®Google Scholar
• Tingstedt B, Johansson P, Andersson B, Andersson R. Predictive factors in pancreatic ductal adenocarcinoma: role of the inflammatory response. Scand J Gastroenterol 2007; 42: 754–9
   PubMed Web of Science ®Google Scholar
• Kang SP, Saif MW. Optimal second-line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data?. J Oral Pathol 2008; 9: 83–90
   Google Scholar
• Andersson B, Aho U, Pendse M-L, Nilsson J, Tingstedt B, Andersson R. Gemcitabine treatment in pancreatic cancer: prognostic factors and outcome. Ann Gastroenterol 2007; 20: 130–7
   Google Scholar
• Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110–7
   PubMed Web of Science ®Google Scholar
• Ruiz van Haperen VWT, Veerman G, Vermorken JB, Peters GJ. 2′,2′–Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA from tumor cell lines. Biochem Pharmacol 1993; 46: 762–6
   PubMed Web of Science ®Google Scholar
• García-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 2003; 9: 5000–8
   PubMed Web of Science ®Google Scholar
• Ruiz van Haperen VWT, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ. Schedule-dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem Pharmacol 1994; 48: 1327–39
   PubMed Web of Science ®Google Scholar
• Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′, 2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updates 2002; 5: 19–33
   PubMed Web of Science ®Google Scholar
• Peters GJ, Clavel M, Noordhuis P, Geyssen GJ, Laan AC, Guastalla J, et al. Clinical phase I and pharmacology study of gemcitabine (2′, 2′-difluorodeoxycytidine) administered in a two-weekly schedule. J Chemother 2007; 19: 212–21
   PubMed Web of Science ®Google Scholar
• Ruiz van Haperen VWT, Veerman G, Eriksson S, Boven E, Stegmann APA, Hermsen M, et al. Development and characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian cancer cell line A2780. Cancer Res 1994; 54: 4138–43
   PubMed Web of Science ®Google Scholar
• Mackey JR, Mani RS, Selner M, Mowles D, Young JD, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58: 4349–57
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66: 3928–35
   PubMed Web of Science ®Google Scholar
• Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004; 10: 6956–61
   PubMed Web of Science ®Google Scholar
• Farrell J, Garcia M, Lai R, Ammar A, Regine W, Abrams R, et al. Human ENT1 is predictive of response in patients with pancreatic cancer treated with gemcitabine: results from the RTOG9704 prospective randomized trial. Pancreas 2007; 35: 401
   Web of Science ®Google Scholar
• Kroep JR, Loves WJP, van der Wilt CL, Alvarez E, Talianidis I, Boven E, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002; 1: 371–6
   PubMed Web of Science ®Google Scholar
• Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007; 96: 457–63
   PubMed Web of Science ®Google Scholar
• Bergman AM, Eijk PP, Ruiz van Haperen VWT, Smid K, Veerman G, Hubeek I, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005; 65: 9510–6
   PubMed Web of Science ®Google Scholar
• Liau SS, Jazag A, Whang EE. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res 2006; 66: 11613–22
   PubMed Web of Science ®Google Scholar
• Liau SS, Whang E. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res 2008; 14: 1470–7
   PubMed Web of Science ®Google Scholar
• Kim MP, Gallick GE. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 2008; 14: 1284–5
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, del Taca M, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005; 68: 110–8
   PubMed Web of Science ®Google Scholar
• Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Met Rev 2007; 26: 85–110
   PubMed Web of Science ®Google Scholar
• Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 2000; 60: 6075–9
   PubMed Web of Science ®Google Scholar
• Tsujie M, Nakamori S, Nakahira S, Takeda S, Takahashi Y, Hayashi N, et al. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model. Pancreas 2006; 33: 142–7
   PubMed Web of Science ®Google Scholar
• Aho U, Zhao X, Löhr M, Andersson R. Molecular mechanisms of pancreatic cancer and potential targets of treatment. Scand J Gastroenterol 2007; 42: 279–96
   PubMed Web of Science ®Google Scholar
• Arlt A, Gherz A, Müerköster S, Vorndamm J, Kruse M-L, Fölsch UR, et al. Role of NF-kB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243–51
   PubMed Web of Science ®Google Scholar
• Hering J, Garrean S, Dekoj TR, Razzak A, Saied A, Trevino J, et al. Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells. Ann Surg Oncol 2007; 14: 3620–8
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 2006; 5: 1387–95
   PubMed Web of Science ®Google Scholar
• Chen P, Chien PY, Khan AR, Sheikh S, Ali SM, Ahmad MU, et al. In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate. Anti-Cancer Drugs 2006; 17: 53–61
   PubMed Web of Science ®Google Scholar
• Bergman AM, Fichtner I, Balzarini J, Fodstad Ø, Kuiper CM, Breistøl K, et al. Oral antitumor effect and in vitro antiproliferative activity of CP-4126, a fatty acid derivative of gemcitabine in cell lines and human cancer xenograft models. Proc Am Assoc Cancer Res 2005; 46: 1444
   Google Scholar
• Bergman AM, Kuiper CM, Noordhuis P, Smid K, Voorn DA, Comijn EM, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts. Nucleosides. Nucleotides Nucleic Acids 2004; 23: 1329–33
   PubMed Web of Science ®Google Scholar
• Adema AD, Smid K, Losekoot N, Myhren F, Sandvold ML, Peters GJ. Fatty acid derivatives of cytarabine and gemcitabine, CP-4055 and CP-4126, show a prolonged cellular retention compared to the parent drug [abstr 5740]. Proc Am Ass Cancer Res 2008; 49
   Google Scholar